Profile data is unavailable for this security.
About the company
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
- Revenue in CHF (TTM)-125.13m
- Net income in CHF-149.14m
- Incorporated2001
- Employees--
- LocationHBM Healthcare Investments AGBundesplatz 1ZUG 6300SwitzerlandCHE
- Phone+41 417107577
- Fax+41 417107578
- Websitehttps://www.hbmhealthcare.com/
Profile
| Management group(s) | HBM Partners Cayman Ltd |
|---|---|
| AIC sector | -- |
| ISIN | CH0012627250 |
| Launch date | 14 Feb 2008 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | CHF |
Objective
HBM Healthcare Investments’ objective is to generate long-term capital gains with investments in private and public companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. Within its target sector, HBM Healthcare Investments invests predominantly in later-stage private companies which are attractively valued and have a convincing business model, including their product pipeline, technology and management. Investments are made worldwide, primarily in Europe, Asia and North America.
Managed by
| Andreas Wicki, Erwin Troxler |
|---|
Management & contract fees
Management fee (paid quarterly): 0.75% of Company assets plus 0.75% of the Company's market capitalisation. Performance fee (paid annually): 15% on increase in value above the high water mark.
